Moreover, combining CD47 blockade with other treatments, such as chemotherapy, monoclonal antibodies (e.g., rituximab for B-cell lymphomas), or immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), can further enhance anti-tumor efficacy. The gene discussed is PDCD1; the disease is neoplasm.